Prognostic importance of cellular DNA content in head-and-neck squamous-cell cancers. A comparison of retrospective and prospective series

• Published in: International journal of cancer Vol. 47; no. 1; p. 31
• Main Authors: Kearsley, J H, Bryson, G, Battistutta, D, Collins, R J
• Format: Journal Article
• Language: English
• Published: United States 02.01.1991
• Subjects: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Squamous Cell - epidemiology; Carcinoma, Squamous Cell - genetics; DNA, Neoplasm - analysis; Female; Flow Cytometry; Head and Neck Neoplasms - epidemiology; Head and Neck Neoplasms - genetics; Humans; Life Tables; Male; Middle Aged; Multivariate Analysis; Ploidies; Prognosis; Prospective Studies; Retrospective Studies; Sex Factors; Survival Analysis
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910470107

Flow cytometric DNA-ploidy measurements were performed on formalin-fixed tumour specimens from 172 patients with squamous-cell cancers (SCCs) of the head and neck region. One hundred and two samples were chosen retrospectively and a further 70 consecutive patients were analysed prospectively in order to assess the prognostic significance of DNA ploidy and DNA index (DI). There were no statistically significant differences between retrospective and prospective groups in regard to age, sex, TNM stage, ploidy or DI. Sixty-seven percent of patients were aneuploid (65% retrospective; 71% prospective). The proportion of aneuploid tumours was significantly higher among poorly differentiated tumours. Survival analysis using Cox multivariate regression modelling revealed that DNA aneuploidy and increasing DI were significant independent prognostic factors for both relapse-free and overall survival. The relapse and death rates among aneuploid subjects were approximately 3 times as high as those for diploid subjects. Patients with a DI greater than 2.11 (hypertetraploidy) experienced a 6.6-fold higher death rate than diploid subjects. These results provide strong support for the incorporation of DNA ploidy profiles into the clinical management of patients with head and neck cancer.